Le mode conseil est activé Arrêter
Pour la navigation rapide entre les blocs

Organisation: Regeneron
LEI 549300RCBFWIRX3HYQ56

Nom de l'organisation
Regeneron Pharmaceuticals Inc
Nom du pays
États-Unis
Pays d'enregistrement
États-Unis
Secteur économique
Production de médicaments et biotechnologies
Dette obligataire
2.000 millions USD

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Dernières données pour

Cotations

Requête envoyé
Accès refusé
Envoyer la requête
Les cotations fournis par les fournisseurs d’information sont de nature indicative

Profile

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

Récompenses

Actualités

02/02/2024 Regeneron Posts Strong Q4 Earnings
02/02/2024 Regeneron: Results Of Operations And Financial Condition, Financial Statements And Exhibits
31/01/2024 Regeneron: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
08/01/2024 Regeneron: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
07/01/2024 Moody's Investors Service upgrades LT- local currency credit rating of Regeneron to "Baa1" from "Baa2"; outlook stable
Toutes les actualités de l'organisation

Documents

Etats financiers IFRS / US GAAP

2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Actions

Dernières émissions

Montrer tout

Dette obligataire par devise

Montrer tout Cacher

Codes

  • LEI
    549300RCBFWIRX3HYQ56
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000872589
  • EIN
    13-3444607

Notations de crédit et notations d’ESG

Macroéconomie

Vous devez vous inscrire pour y accéder.